Investment
Features
FeesSafety
Academy
More
Pluang+

New ETF WEEL uses the 'wheel' options strategy to generate steady income with 11.86% yield.

Others
26 Aug 2026
24/7 Wall Street
View Source
Bullish
New ETF WEEL uses the 'wheel' options strategy to generate steady income with 11.86% yield.

The Peerless Options Wheel Income ETF (WEEL) is the first ETF to implement the 'wheel' strategy, which involves selling cash-secured puts and covered calls on sector ETFs to generate consistent option premiums. This approach suits volatile, range-bound markets and aims for income rather than capital gains, currently offering an 11.86% distribution rate. WEEL actively manages a diverse portfolio including Treasury bills and sector ETFs like gold miners and biotech, providing a hands-off way for investors to access this complex options strategy despite its 0.99% net expense ratio. This ETF simplifies the demanding process of managing multiple options trades for individual investors.

More News

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...

Market News
Bullish
1 hour ago
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...

Market News
Bullish
1 hour ago
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...

Company Fundamentals
Bullish
3 hours ago
Solana stablecoin reserves drop $1.12B in 16 days, signaling increased selling pressure and potential slippage risks.

Solana stablecoin reserves drop $1.12B in 16 days, signaling increased selling pressure and potential slippage risks.

Solana's stablecoin reserves fell from $17.45 billion on September 25 to $16.33 billion by October 11, a 6.4% decline indicating that $1.12 billion left the chain. This reduction reflects actual sell or transfer activity, not price changes, and sugge...

Market News
Bearish
4 hours ago
Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy announced it repurchased $176 million of its STRC preferred stock while acquiring 334 BTC in Q3 2026, reporting a $21 billion gain on digital assets. Michael Saylor confirmed that Bitcoin purchases will continue, framing the STRC buyback as ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App